Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS finalises Amylin buy, Lilly cashes in too

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb has completed its $7 billion acquisition of Amylin for $31 per share, paving the way for AstraZeneca to get in on the action. The UK firm has paid $3.2 billion to Amylin for an equal share in the profits generated by Amylin's diabetes drugs as part of an expanded diabetes alliance between the two firms. AstraZeneca also said it will also be buying the right to have a say in key strategic and financial decisions relating to the portfolio for $135 million. In June, Scrip highlighted the two pharmaceutical firms, which have worked together in diabetes since 2007, as prime contenders for the Amylin bid (, 27 June 2012). AstraZeneca's involvement in the BMS-Amylin deal was little surprise, as news of the acquisition broke, Scrip took a look at the events leading up to the deal (, 2 July 2012). Meanwhile, Lilly has upped its financial guidance after receiving $1.26 billion from its former partner Amylin for financial obligations relating to exenatide (Byetta, Bydureon). Lilly says it will use the money to develop its pipeline.

You may also be interested in...

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.

Lilly Pays KeyBioscience $55m Up Front to Expand Its Early Diabetes Pipeline

Lilly nabbed multiple molecules for its early-stage diabetes portfolio via a $55m-plus partnership with KeyBioscience, making sure that the big pharma's pipeline continues to add products to its largest franchise.

Smaller EU Countries Call for More Comparative Trials

More should be done to incentivize comparative clinical trials so as to allow better decisions on drug pricing to be taken, said Austria’s representative at a recent meeting of EU health ministers.


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts